IDKmonitor Etanercept Drug Level ELISA 96 wells
Therapeutic Drug Monitoring
The IDKmonitor Etanercept Drug Level ELISA kit is a microplate-based quantitative enzyme linked immunosorbent assay (ELISA) for the determination of free Etanercept from plasma or serum samples.
The Etanercept ELISA is based on a sandwich enzyme immunoassay technique with a Etanercept specific capture antibody adsorbed on a microplate and a detection antibody labeled with horseradish peroxidase (HRP).
This test is intended to quantify the amount of free drug (Etanercept) to evaluate the efficacy of drug and to investigate Primary non-response and loss of response.
Being able to stratify patients according to whether they are likely to benefit from their Etanercept treatment has both clinical and economic advantages because patients may not respond equally to Etanercept.
Some patients will respond well with fewer symptoms with a reduction in inflammatory biomarkers (e.g. CRP) and Disease activity scores, while others may fail to respond during the induction phase of treatment, or lose response over time.
IDKmonitor® assays from BIOHIT HealthCare are highly specific for the target drug and are used widely for routine clinical and research applications. The IDKmonitor® Etanercept Drug Level ELISA may help:
Assess risk of and manage primary non-response
Predict the long term outcome and identify loss of response
Predict response to therapy withdrawal
Predict efficacy of re-initiating therapy after drug holiday
Direct the switching to another class of drug
The IDKmonitor® ELISA for the determination of the drug level of Etanercept (e.g. Enbrel®) in EDTA plasma and serum measures free Etanercept quantitatively, giving the treating physician an opportunity to monitor and optimise therapy.
The assay determines the quantity of free Etanercept (therapeutic antibody against TNFα) in EDTA plasma or serum samples by capturing the free (unbound) Etanercept using a specific monoclonal anti-Etanercept antibody that coats the plate.
Quantifies free Etanercept drug levels in Serum and Plasma
Microplate coated with highly specific anti-Etanercept Ab
6 calibrators, 2 controls
Capacity for 40 samples in duplicate
Reportable range 4.15-225 ng/ml
Total incubation time 130 minutes
Automatable on ELISA automates (e.g. Dynex D2)
Highly specific quantification of Etanercept
No cross reactivity with Infliximab, Adalimumab or Golimumab
May helps predict Primary non-response, loss of response, non remission
Applicable to Rheumatology
+2 to +8